Received Mar 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 4N222 | IM |
patient was administered with a priorix vaccine intramuscularly instead of subcutaneous; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate route of vaccination in a 44-year-old male patient who received MMR (Priorix) (batch number 4N222, expiry date 13-SEP-2026) for prophylaxis. On 15-MAR-2025, the patient received Priorix (intramuscular). On 15-MAR-2025, an unknown time after receiving Priorix, the patient experienced inappropriate route of vaccination (Verbatim: patient was administered with a priorix vaccine intramuscularly instead of subcutaneous). The outcome of the inappropriate route of vaccination was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-MAR-2025 Pharmacist called to report that a patient was administered with a Priorix vaccine intramuscularly instead of subcutaneous, which led to Inappropriate route of vaccination.